Cytodyn Inc (CYDY)

[Bobbyinvest]

Not quite: there is more lol. I only posted the simple math. We are at about to 652,000,000 mil committed and obligated.

Take the 580 with all warrants + 43m + 2m from preferred + 16.4 more preferred + 11m for other misc purposes.

1)
This number is based on 399,156,340 shares of common stock outstanding as of December 6, 2019, which excludes (i) 43,773,638 shares of common stock reserved for the issuance upon the conversion or redemption of outstanding convertible notes, (ii) 921,000 shares of common stock issuable upon conversion of outstanding shares of our Series B Convertible Preferred Stock (“Series B Preferred Stock”), and 456,920 shares of common stock that would be issuable at our election in lieu of cash as accrued dividends, if declared thereunder, (iii) 16,406,000 shares of common stock issuable upon conversion of outstanding shares of our Series C Convertible Preferred Stock (“Series C Preferred Stock”), and 633,289 shares of common stock that are issuable at the holder’s election in lieu of cash as dividends, (iv) 162,040,383 shares of common stock that may be issued upon the exercise of outstanding warrants, with a weighted average exercise price of $0.65 per share, (v) 16,653,710 shares of common stock that may be issued upon the exercise of outstanding options, with a weighted average exercise price of $0.61 per share, (vi) 8,222,306 shares of common stock reserved for future issuance under the 2012 Equity Incentive Plan, (vii) 2,620,000 shares of common stock earned by, but not yet issued to, our investment bank for advisory services in connection with our recent acquisition transaction with ProstaGene, LLC and other advisory services and (viii) 379,880 shares of common stock earned by management but not yet issued pursuant to annual bonus awards for fiscal year 2018.
(2)
This number is based on 399,156,340 shares of common stock outstanding as of December 6, 2019, which excludes (i) 43,773,638 shares of common stock reserved for the issuance upon the conversion or redemption of outstanding convertible notes, (ii) 921,000 shares of common stock issuable upon conversion of outstanding shares of our Series B Preferred Stock, and 456,920 shares of common stock that would be issuable at our election in lieu of cash as accrued dividends, if declared thereunder, (iii) 16,406,000 shares of common stock issuable upon conversion of outstanding shares of our Series C Preferred Stock, and 633,289 shares of common stock that are issuable at the holder’s election in lieu of cash as dividends, (iv) 162,040,383 shares of common stock that may be issued upon the exercise of outstanding warrants, with a weighted average exercise price of $0.65 per share, (v) 16,653,710 shares of common stock that may be issued upon the exercise of outstanding options, with a weighted average exercise price of $0.61 per share, (vi) 8,222,306 shares of common stock reserved for future issuance under the 2012 Equity Incentive Plan, (vii) 2,620,000 shares of common stock earned by, but not yet issued to, our investment bank for advisory services in connection with our recent acquisition transaction with ProstaGene, LLC and other advisory services, (viii) 379,880 shares of common stock earned by management but not yet issued pursuant to annual bonus awards for fiscal year 2018 and (ix) 1,926,248 shares of common stock issuable upon exercise of warrants sold in this offering.